Treatment of Active Tuberculosis
For drug-susceptible pulmonary TB in adults, a 4-month regimen is now the preferred treatment, and for children aged 3 months to 16 years with nonsevere TB, a 4-month regimen of 2HRZ(E)/2HR is strongly recommended over the traditional 6-month regimen 1.
Drug-Susceptible TB Treatment
Adults with Pulmonary TB
The 2025 ATS/CDC/ERS/IDSA guidelines represent a paradigm shift from the 40-year standard of 6-month therapy 1. The new 4-month all-oral regimen offers:
- Shorter treatment duration improving adherence and quality of life
- Reduced pill burden for patients
- Maintained efficacy with acceptable safety profiles
The standard regimen consists of:
- Initial phase (2 months): Isoniazid (H), Rifampin (R), Pyrazinamide (Z), and Ethambutol (E)
- Continuation phase (2 months): Isoniazid and Rifampin
Children and Adolescents (3 months to 16 years)
For nonsevere TB without MDR/RR-TB suspicion, the guideline provides a strong recommendation with moderate certainty of evidence for the 4-month regimen: 2HRZ(E)/2HR 1.
Common pitfall: Do not use the shortened regimen in children with severe TB, suspected drug resistance, or CNS involvement—these require longer treatment courses.
Drug-Resistant TB Treatment
Rifampin-Resistant, Fluoroquinolone-Susceptible TB
For adolescents ≥14 years and adults, a 6-month BPaLM regimen (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin) is strongly recommended over 15-month or longer regimens 1. This represents a dramatic reduction in treatment duration from 15+ months to just 6 months, despite very low certainty of evidence—the recommendation strength reflects the substantial improvement in quality of life and treatment completion rates.
Key Advantages of BPaLM:
- All-oral regimen (no injectable agents)
- Dramatically shorter duration (6 vs 15+ months)
- Improved tolerability compared to traditional second-line regimens
- Better treatment adherence due to shorter course
Critical caveat: This regimen is specifically for rifampin-resistant, fluoroquinolone-susceptible TB. Fluoroquinolone resistance requires alternative regimens per current drug-resistant TB guidelines.
Treatment Monitoring
Directly Observed Therapy (DOT)
DOT remains the standard of care for ensuring treatment adherence 2, 3. However, virtual treatment monitoring using digital technologies is increasingly accepted as a patient-centered alternative 2.
Treatment Completion Criteria
- Clinical improvement: Resolution of symptoms (cough, fever, weight gain)
- Microbiological response: Negative cultures
- Radiographic improvement: Though imaging may lag behind clinical improvement
Important consideration: Treatment duration is based on the regimen started, not on when cultures convert to negative. Complete the full course even if cultures clear early.
Special Populations
HIV Co-infection
Patients with HIV-TB co-infection face additional challenges including:
- Drug interactions between antiretrovirals and rifamycins
- Immune reconstitution inflammatory syndrome (IRIS) risk
- May require longer treatment courses depending on CD4 count and disease severity 3
Pregnancy
TB treatment should not be delayed in pregnancy. The standard regimen can be used, though streptomycin should be avoided due to ototoxicity risk to the fetus 4.
Adverse Drug Reactions
Monitor for common toxicities:
- Hepatotoxicity: Isoniazid, rifampin, pyrazinamide (monitor liver enzymes)
- Peripheral neuropathy: Isoniazid (give pyridoxine supplementation)
- Optic neuritis: Ethambutol (baseline and monthly vision checks)
- Hyperuricemia: Pyrazinamide
- Drug interactions: Rifampin is a potent CYP450 inducer
Management approach: When adverse reactions occur, identify the offending agent and substitute with an alternative drug rather than stopping all therapy, to maintain treatment efficacy 5.
Treatment Failure Considerations
If patients fail to respond clinically or microbiologically by 2-3 months:
- Reassess adherence (most common cause)
- Consider drug resistance (obtain drug susceptibility testing)
- Evaluate for malabsorption of medications
- Rule out alternative diagnoses or complications
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB underscores the critical importance of prompt diagnosis, appropriate initial regimen selection, and ensuring treatment completion 3, 6.